- Wall Street indices open mostly higher
- US100 halts recovery move at 38.2% retracement
- Texas Instruments jumps 7% after earnings
Wall Street indices launched today's trading little change, in spite of a big post-earnings jump in Tesla shares. S&P 500 opened 0.2% higher, Dow Jones gained 0.1% at the opening, Nasdaq jumped 0.6%, while small-cap Russell 2000 slumped 0.4%
Source: xStation5
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appPost-earnings spike in Tesla shares, in spite of earnings itself being a disappointment, is supporting Nasdaq-100 futures (US100) today, making the index the best performing Wall Street benchmark. Taking a look at US100 chart at H1 interval, we can see that the index broke above the upper limit of a local market geometry at 17,585 pts yesterday and continued to gain overnight. However, advance was halted at the 17,775 pts resistance zone, marked with previous local high, 200-hour moving average (purple line) and 38.2% retracement of the downward impulse launch in the second half of March 2024. Supply-side reaction to this hurdle signals the index may resume decline. If this is the case, the near-term support to watch can be found in the 17,500 pts area, where 23.6% retracement can be found.
Company News
Vertiv Holdings (VRT.US) rallies at double-digit pace following release of Q1 earnings. Company reported net sales of $1.64 billion (exp. $1.62 billion), driven by $925 million in Americas net sales. Adjusted operating margin reached 15.2% (exp. 13.5%), with company's largest geographical market (Americas) being also its most profitable one with a margin of 20.3%. Net orders jumped 60% YoY during the period. Adjusted EPS of $0.43 was higher than $0.36 expected. Vertiv expects Q2 net sales of $1.90-1.95 billion (exp. $1.9 billion) and Q2 adjusted EPS of $0.53-0.57 (exp. $0.55). Company also upgraded its full-year forecast and is now expecting net sales to reach $7.54-7.69 billion, up from previous range of $7.52-7.66 billion. Full-year adjusted EPS is now seen at $2.29-2.35, up from previous forecast of $2.20-2.26.
Texas Instruments (TXN.US) trades higher after reporting better-than-expected Q1 results. Company reported a 16% YoY revenue drop to $3.66 billion (exp. $3.60 billion), with Analog segment revenue dropping 14% YoY to $2.84 billion (exp. $2.81 billion). Operating profit dropped 34% YoY to $1.29 billion (exp. $1.12 billion). Research & developments expenses were 5.1% YoY higher at $478 million (exp. $468 million), while capital expenditures increased 27% YoY to $1.25 billion (exp. $1.21 billion). Adjusted EPS declined to $1.20 from $1.85 a year ago. Texas Instruments expects Q2 revenue of $3.65-3.95 billion (exp. $3.78 billion) and EPS of $1.05-1.25 (exp. $1.17).
General Dynamics (GD.US) reported 8.6% YoY drop in Q1 revenue to $10.73 billion (exp. $10.28 billion). Technologies segment revenue declined 0.8% YoY to $3.21 billion (exp. $3.22 billion), Marine Systems revenue increased 11% YoY to $3.33 billion (exp. $3.04 billion) and Combat Systems revenue rallied 20% YoY to $2.10 billion. Aerospace revenue increased 10% YoY to $2.08 billion (exp. $2.28 billion). Company-wide operating margin reached 9.7% (exp. 10.2%), with Combat Systems having the highest margin at 13.4% (exp. 13.9%). Order backlog increased 4.3% YoY to $93.7 billion. Adjusted EPS reached $2.88 (exp. $2.91). Company reported a negative free cash flow of $437 million, while market expected a positive $881 million.
Texas Instruments (TXN.US) launched today's trading with a big bullish price gap. While the company reported results that were weaker than a year ago, they were better than expected. Stock broke above resistance zone ranging around $175 mark and reached the highest level in almost 9 months. Source: xStation5
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.